News and Events
10/31/2013 - Pluripotent stem cell expert Hongkui Deng Joins ImStem's Scientific Advisory Board
Farmington, CT -- ImStem Biotechnology Inc., Oct. 31, 2013 -ImStem Biotechnology, (ImStem) announced today that Dr. Hongkui Deng, Ph.D. has been appointed to the Company's Scientific Advisory Board. Dr. Deng is an expert in pluripotent stem cell technology. He is the first investigator in the world who have successfully reprogramming adult cells into induced pluripotent stem cells (iPS) with chemical compounds only, which avoids the introduce of foreign gene into the cells and is big setup towards the safe use of iPS in the future.
Dr. Deng now is a Senior Investigator of Peking-Tsinghua Center for Life Sciences and a professor of cell biology at the College of Life Sciences of Peking University since 2001. Dr. Deng is the first investigator in China to receive a Bill and Melinda Gates Foundation grant. He is also a winner of Lilly-Asian Scientific Excellent Award in 2006, as well as a winner of Sanofi-Aventis / Cell Research Outstand Paper Award in 2010. He is a well known and respected cell biologist being highlighted in articles in Nature Science and Time Magazine.
Prior to Peking University, Dr. Deng was the Director of Molecular Biology at Viacell Inc working on ex vivo expansion of human hematopoietic stem cells. From 1995 to 1997 he was an Aaron Diamond Postdoctoral fellow with Dan R. Littman at the NYU School of Medicine’s Skirball Institute, where he identified major co-receptors for HIV entry into cells. He obtained his master degree in Immunology from Shanghai Second Medical University in 1987 and his Ph.D. of Immunology in 1995 from University of California, Los Angeles, where he worked with Eli Sercarz on the function of histocompatibility molecules in antigen presentation.
"I am excited to join ImStem's Advisory Board and help with their product development," stated Dr. Deng. "The Company's novel approach to make mesenchymal stem cell from human embryonic stem cells will greatly expedite the clinical use of human embryonic stem cell.
The Company's Chief Scientific Officer, Dr. Ren-He Xu, said, "We are very pleased to have Dr. Deng as our Scientific Advisory Board member, Dr. Deng's expertise in pluripotent stem cell biology and immunology will greatly help us build our product portfolio and improve our technology development.”
|(From left to right, Dr. Xiaofang Wang, Dr. Hongkui Deng, Dr. Ren-He Xu)|
About ImStem Biotechnology, Inc.
ImStem is a biotechnology company developing therapies and stem cell product for tissue repair and autoimmune diseases. For more information about ImStem, visit www.imstem.com.
Investor and Media Relations